In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
“Metastatic colorectal cancer remains a formidable challenge with limited effective therapies. The promising early results with petosemtamab offer hope for advancing care and bringing new treatment ...
Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody ...
The Common Terminology Criteria for Adverse Events can be found at [201] and the WHO criteria can be found at [202]. 5-FU: 5-fluorouracil; ADR: Adverse drug reaction; CRC: Colorectal cancer; mCRC: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback